CHMP postive for Deqsiga intended for replacement therapy in people with primary or secondary immunodeficiencies and immunomodulation – Takeda
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Deqsiga, intended for replacement therapy in people… read more.
